| A single inhalation of vapor from dried toad secretion containing 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of … MV Uthaug, R Lancelotta, K Van Oorsouw, KPC Kuypers, N Mason, J Rak, ... Psychopharmacology 236 (9), 2653-2666, 2019 | 167 | 2019 |
| A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy JB Luoma, C Chwyl, GJ Bathje, AK Davis, R Lancelotta Journal of Psychoactive Drugs 52 (4), 289-299, 2020 | 163 | 2020 |
| 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety AK Davis, S So, R Lancelotta, JP Barsuglia, RR Griffiths The American journal of drug and alcohol abuse 45 (2), 161-169, 2019 | 127 | 2019 |
| The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption AK Davis, JP Barsuglia, R Lancelotta, RM Grant, E Renn Journal of Psychopharmacology 32 (7), 779-792, 2018 | 127 | 2018 |
| Prospective examination of synthetic 5-methoxy-N, N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment MV Uthaug, R Lancelotta, A Szabo, AK Davis, J Riba, JG Ramaekers Psychopharmacology 237, 773-785, 2020 | 87 | 2020 |
| Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study J Barsuglia, AK Davis, R Palmer, R Lancelotta, AM Windham-Herman, ... Frontiers in psychology 9, 2459, 2018 | 70 | 2018 |
| Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes G Agin-Liebes, TF Haas, R Lancelotta, MV Uthaug, JG Ramaekers, ... ACS Pharmacology & Translational Science 4 (2), 543-552, 2021 | 58 | 2021 |
| The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N, N‐dimethyltryptamine (5‐MeO‐DMT) JT Reckweg, MV Uthaug, A Szabo, AK Davis, R Lancelotta, NL Mason, ... Journal of Neurochemistry 162 (1), 128-146, 2022 | 46 | 2022 |
| The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects MV Uthaug, AK Davis, TF Haas, D Davis, SB Dolan, R Lancelotta, ... Journal of Psychopharmacology 36 (3), 309-320, 2022 | 41 | 2022 |
| Synthesis and Characterization of 5-MeO-DMT succinate for clinical use AM Sherwood, R Claveau, R Lancelotta, KW Kaylo, K Lenoch ACS omega 5 (49), 32067-32075, 2020 | 33 | 2020 |
| Use of benefit enhancement strategies among 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) users: Associations with mystical, challenging, and enduring effects RL Lancelotta, AK Davis Journal of Psychoactive Drugs 52 (3), 273-281, 2020 | 26 | 2020 |
| Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects ND Sepeda, JM Clifton, LY Doyle, R Lancelotta, RR Griffiths, AK Davis Journal of Psychedelic Studies 4 (2), 114-122, 2020 | 20 | 2020 |
| A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in … MV Uthaug, R Lancelotta, AM Ortiz Bernal, AK Davis, JG Ramaekers Journal of Psychedelic Studies 4 (2), 104-113, 2020 | 18 | 2020 |
| Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms A Nikolaidis, R Lancelotta, N Gukasyan, RR Griffiths, FS Barrett, AK Davis Journal of Affective Disorders 324, 239-249, 2023 | 14 | 2023 |
| Reactivations after 5-methoxy-N, N-dimethyltryptamine use in naturalistic settings: an initial exploratory analysis of the phenomenon’s predictors and its emotional valence AM Ortiz Bernal, CL Raison, RL Lancelotta, AK Davis Frontiers in psychiatry 13, 1049643, 2022 | 11 | 2022 |
| 5-MeO-DMT and subjective improvements in post traumatic stress disorder KE Cox, R Lancelotta, J Barsuglia, AK Davis annual conference of the Maryland Psychological Association, Baltimore, MD, 2018 | 6 | 2018 |
| Therapeutic potential of fast-acting synthetic tryptamines R Lancelotta, AK Davis Handbook of medical hallucinogens, 215-232, 2021 | 4 | 2021 |
| Reactivations after 5-MeO-DMT use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence AM Ortiz Bernal, CL Raison, R Lancelotta, AK Davis Frontiers in Psychiatry 2706, 2019 | 3 | 2019 |
| Clinical consideration of 5-meodmt AM Sherwood, KV Kaylo, RB Kargbo, AK Davis, R Lancelotta, MV Uthaug, ... International forum on consciousness. https://www. resea rchga te. net/publi …, 2019 | 3 | 2019 |
| Subjective improvements in substance use problems following 5-MeO-DMT use in an international sample KE Cox, SA Moshman, JP Barsuglia, R Lancelotta, AK Davis BPRU Poster Symposium, Baltimore, MD, 2018 | 2 | 2018 |
Alan K. DavisThe Ohio State UniversityVerified email at osu.edu
